Jaakko Koskenniemi
jajoko@utu.fi |
Publications
- Islet autoimmunity and progression to type 1 diabetes in the Finnish DIPP study: comparison between genetically susceptible children with and without an affected first-degree relative (2026)
- Diabetologia
(A1 Refereed original research article in a scientific journal) - Thyroid autoimmunity and the subsequent development of islet and celiac autoimmunity in the TEDDY study (2026)
- American Journal of Epidemiology
(A1 Refereed original research article in a scientific journal) - Altered Glucagon Response to Oral Glucose in Individuals at Different Stages of Type 1 Diabetes Development (2025)
- Journal of Clinical Endocrinology and Metabolism
(A1 Refereed original research article in a scientific journal) - β-Cell Function and Glucose Tolerance in Persons With Multiple Islet Autoantibodies Randomized to a Gluten-free Diet (2025)
- Journal of the Endocrine Society
(A1 Refereed original research article in a scientific journal) - Genetic evidence for efficacy of targeting IL-2, IL-6 and TYK2 signalling in the prevention of type 1 diabetes: a Mendelian randomisation study (2024)
- Diabetologia
(A1 Refereed original research article in a scientific journal) - Pubertal testicular volume references for ruler, orchidometer, and ultrasonography measurements based on a longitudinal follow-up (2024)
- Andrology
(A1 Refereed original research article in a scientific journal) - Extremely Early Appearance of Islet Autoantibodies in Genetically Susceptible Children (2023)
- Pediatric Diabetes
(A1 Refereed original research article in a scientific journal) - Serum APOC1 levels are decreased in young autoantibody positive children who rapidly progress to type 1 diabetes (2023)
- Scientific Reports
(A1 Refereed original research article in a scientific journal) - Exploring Minimally Invasive Approach to Define Stages of Type 1 Diabetes Remotely (2022)
- Diabetes Technology and Therapeutics
(A1 Refereed original research article in a scientific journal) - INnoVative trial design for testing the Efficacy, Safety and Tolerability of 6-month treatment with incretin-based therapy to prevent type 1 DIAbetes in autoantibody positive participants: A protocol for three parallel double-blind, randomised controlled trials (INVESTDIA) (2022)
- Diabetic Medicine
(A1 Refereed original research article in a scientific journal)



